This company finances 1 out of 10 apartment builds in Australia. Many investors have never heard of it
Qualitas steps in where Australian banks increasingly won’t, funding apartment and commercial property projects and getting paid in several ways as those deals are made and managed. It’s grown quickly and is now pushing into Europe, but the same real-estate cycle, tighter rules, or stumbles on its expansion could test how durable that growth really is.Read more
Why this rare earths stock could make millions without mining an ounce
China still controls the hardest step in making rare earth magnets, but Ionic Rare Earths aims to sidestep that by recycling magnet waste right next to new factories in the West. The big question is whether it can scale this plug-in recycling model fast enough, before cash needs and fierce competition catch up.Read more
This small biotech is developing technology that could potentially change how tissue is rebuilt
Conexeu is building an injectable material that turns into a gel inside the body, aiming to help damaged tissue rebuild itself instead of just being covered up. The big question is whether it can clear regulators and win adoption in wound care first—then expand into areas like dentistry, animal health, and even cosmetic use.Read more
When GPS fails: this small cap is fixing a $54B drone problem
Key Points: Sparc AI (CSE:SPAI) is tackling a growing global problem: drones and aircraft failing when GPS is jammed or spoofed, a problem already driving massive government losses globally. Its Overwatch platform is a software solution to the hardware problem, using AI and existing sensors making it highly scalable across fleets.Read more
This OVERLOOKED Gold Stock Could TRIPLE - 3.3M Ounces, Bottom-of-Peer Valuation
A small Canadian explorer says its Kena project already holds a large gold deposit and could grow further by folding in past drilling and adding copper and silver for the first time. The next drill season and a new independent resource update could be the moment that proves whether this discount is deserved or not.Read more
Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market
Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.Read more
This small cap is building the AI workforce of the future
Key Takeaways EVA Live (Nasdaq:GOAI) has launched NeuroServer , a purpose-built AI system trained specifically for digital advertising rather than built on off-the-shelf AI models. Its custom AI build was trained using reinforcement learning in a marketing agency environment, leading to higher ROI for companies using Eva Live's tech than without.Read more
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
Roche is lining up a new wave of potential hit medicines across obesity, cancer, and multiple sclerosis, with many important trial results expected soon. The big question is whether these programs succeed before tougher competition and upcoming patent expiries start to bite.Read more
